Abstract
Optimisation of a high-throughput screening hit resulted in the discovery of 4-(substituted amino)-1-alkyl-pyrazolo[3,4-b]pyridine-5-carboxamides as potent and selective inhibitors of Phosphodiesterase 4 (PDE4). Herein, we describe early SAR studies around this novel template highlighting preferred substituents and rationalization of SAR through X-ray crystal structures of analogues bound to the PDE4 active site. Pyrazolopyridine 20a was found to be a potent and selective PDE4 inhibitor which also inhibits LPS induced TNF-alpha production from isolated human peripheral blood mononuclear cells and has an encouraging rat PK profile suitable for oral dosing.
MeSH terms
-
Aminopyridines / pharmacology
-
Animals
-
Benzamides / pharmacology
-
Chemistry, Pharmaceutical / methods*
-
Crystallography, X-Ray / methods
-
Cyclic Nucleotide Phosphodiesterases, Type 4 / chemistry*
-
Cyclopropanes / pharmacology
-
Drug Design
-
Humans
-
Leukocytes, Mononuclear / cytology
-
Leukocytes, Mononuclear / metabolism
-
Models, Biological
-
Models, Chemical
-
Phosphodiesterase 4 Inhibitors*
-
Pyrazoles / chemical synthesis*
-
Pyrazoles / pharmacokinetics*
-
Pyridines / chemical synthesis*
-
Pyridines / pharmacokinetics*
-
Pyrrolidinones / chemistry
-
Rats
-
Rolipram / pharmacology
-
Tumor Necrosis Factor-alpha / metabolism
Substances
-
Aminopyridines
-
Benzamides
-
Cyclopropanes
-
Phosphodiesterase 4 Inhibitors
-
Pyrazoles
-
Pyridines
-
Pyrrolidinones
-
Tumor Necrosis Factor-alpha
-
pyrazolopyridine
-
Roflumilast
-
Cyclic Nucleotide Phosphodiesterases, Type 4
-
Rolipram